Abstract
Preclinical PET imaging studies with 124I-CLR1404, a radioiodinated phospholipid ether analog, indicate selective tumor uptake and prolonged tumor retention in 52/54 solid cancers. The agent does not localize in either inflammatory sites or premalignant lesions and thus affords excellent promise for therapy of solid malignancies due to its prolonged tumor cell retention properties. The overall objective of this study was to evaluate the therapeutic efficacy of 131I-CLR1404 in a variety of solid human xenograft cancer models.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
